BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BRCA1 plays a critical role in the regulation of homologous recombination (HR)-mediated DNA double-strand break repair. BRCA1-deficient cancers have evolved to tolerate loss of BRCA1 function. This renders them vulnerable to agents, such as PARP inhibitors, that are conditionally 'synthetic lethal' with their underlying repair defect. Recent studies demonstrate that BRCA1-deficient cells may acquire resistance to these agents by partially correcting their defect in HR-mediated repair, either through reversion mutations in BRCA1 or through 'synthetic viable' loss of 53BP1. These findings and their clinical implications will be reviewed in this article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells
Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81847-4 · Cited by 1,459
Human CtIP promotes DNA end resection
Sartori, A. A., Lukas, C., Coates, J., Mistrik, M., Fu, S., Bartek, J., Baer, R., Lukas, J., & Jackson, S. P. (2007) · Nature · doi:10.1038/nature06337 · Cited by 1,362
Brca1 Controls Homology-Directed DNA Repair
Moynahan, M. E., Chiu, J. W., Koller, B. H., & Jasin, M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80202-6 · Cited by 1,245
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice
Ding, S., Wu, X., Li, G., Han, M., Zhuang, Y., & Xu, T. (2005) · Cell · doi:10.1016/j.cell.2005.07.013 · Cited by 1,009
Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage
Scully, R., Chen, J., Ochs, R. L., Keegan, K., Hoekstra, M., Feunteun, J., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80503-6 · Cited by 900
Cited by
Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination
Sivanand, S., Rhoades, S., Jiang, Q., Lee, J. V., Benci, J., Zhang, J., Yuan, S., Viney, I., Zhao, S., Carrer, A., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.008 · Cited by 295
“…early onset 1 (BRCA1) and p53-binding protein 1 (53BP1) are key upstream factors that determineDNA repair pathway choice, and these factors mutually inhibit one another’s binding at nucleosomes flanking DSB sites (Aly and Ganesan, 2011; Panier and Boulton, 2014; Zimmermann and de Lange, 2014).”
BackgroundMladenov, E., Magin, S., Soni, A., & Iliakis, G. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00113 · Cited by 290
Global Genetic Networks and the Genotype-to-Phenotype Relationship
Costanzo, M., Kuzmin, E., van Leeuwen, J., Mair, B., Moffat, J., Boone, C., & Andrews, B. (2019) · Cell · doi:10.1016/j.cell.2019.01.033 · Cited by 241
“Mechanistically, this interaction represents the re-activation of the homologous recombination (HR) machinery, which is compromised in the absence of BRCA1, by inactivating the negative HR-regulator, 53BP1 (Aly and Ganesan, 2011).”
BackgroundVitamin D/vitamin D receptor axis regulates DNA repair during oncogene-induced senescence
Graziano, S., Johnston, R., Deng, O., Zhang, J., & Gonzalo, S. (2016) · Oncogene · doi:10.1038/onc.2016.77 · Cited by 60
Metadata
- Authors
- Aly, A., & Ganesan, S.
- Venue
- Journal of Molecular Cell Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-01-30
- Volume
- 3
- Issue
- 1
- Pages
- 66-74
- ISSN
- 1674-2788 (ISSN-L)
- OpenAlex
- W2171297405
- Cited by
- 107
- References
- 23
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. https://app.cochat.ai/papers/10.1093/jmcb/mjq055
- The paper
- Aly, A., & Ganesan, S. (2011). BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. Journal of Molecular Cell Biology. https://doi.org/10.1093/jmcb/mjq055
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.